Citius Oncology Raises $7.48M in Direct Offering

Citius Oncology ( (CTOR) ) has issued an announcement.

On September 9, 2025, Citius Oncology entered into agreements for a registered direct offering and concurrent private placement, raising approximately $7.48 million in net proceeds. The offering involved the sale of 5,142,858 shares and warrants to purchase the same number of shares, with the transaction closing on September 10, 2025. This financial move is expected to impact the company’s operations by providing additional funds, while also temporarily restricting further stock issuance for 65 days post-closing.

The most recent analyst rating on (CTOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Spark’s Take on CTOR Stock

According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.

Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.

To see Spark’s full report on CTOR stock, click here.

More about Citius Oncology

Citius Oncology, Inc. is a platform focused on developing and commercializing novel targeted oncology therapies. Its primary asset, LYMPHIR, was approved by the FDA in August 2024 for treating adults with relapsed or refractory cutaneous T-cell lymphoma. The company is a subsidiary of Citius Pharmaceuticals, which owns 79% of Citius Oncology.

Average Trading Volume: 1,771,053

Technical Sentiment Signal: Sell

Current Market Cap: $144.2M

For detailed information about CTOR stock, go to TipRanks’ Stock Analysis page.